This is an Open Access article licensed under the terms of the Creative Commons AttributionNonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only. 
Introduction
Colon cancer has become one of the most common malignant cancers worldwide, leading to half a million deaths each year [1] . Numerous reports have confirmed that multiple genetic changes that are critical for colon cancer initiation and progression, such as the Wnt/ β-Catenin pathway, Ras/Raf pathway and p53 pathway [2, 3] .
Sox4 is a 47-kDa protein, which belongs to the sex-determining region Y (SRY) box family, consisting of 20 highly conserved transcription factors [4] . Initial studies have demonstrated that Sox4 is required for the development of several tissues or organs, including heart, lymphocytes, and thymocytes [5] . Indeed, ablation of Sox4 in mice resulted in cardiac defects and reduced proliferative capacity of B-cell progenitors [6, 7] . Subsequent studies in recent years suggested that Sox4 might be an important oncogene contributing to tumor progression [8] . For instance, its expression was dramatically elevated in tumors of the prostate, bladder, breast and lung [9] [10] [11] . Besides, nuclear Sox4 expression was also increased in colon tumor tissues relative to non-tumor colon tissues [12] . Moreover, its overexpression was closely correlated with tumor invasion and metastasis [12] , suggesting its potential significance in the clinical and prognostic implications. However, until now, the molecular mechanism by which Sox4 exerts its activity in tumor progression and aggressiveness remains poorly understood.
In the current study, we performed a PCR-based microarrays using cDNA prepared from Sox4-overexpressed SW480 cells. Furthermore, Cyr61, a secreted extracellular matrixassociated signaling protein, was identified as a novel transcriptional target of Sox4 Our results suggest that the oncogenic roles of Sox4 in colon cancer cells might be, at least in part, dependent on its up-regulation of Cyr61.
Material and Methods
Tissue Samples 20 pairs of human colon cancer tissues, adjacent non-cancerous normal tissues were collected from routine therapeutic surgery at our department. All samples were obtained with informed consent and approved by Henan Provincial People's Hospital review board.
Cell Culture
Two colon cancer cell lines (SW480 and HCT116) were purchased from Cell Bank of Type Culture Collection of Chinese Academy of Sciences (CAS, Shanghai, China) and cultured in modified Eagle's medium (MEM, Gibco, Shanghai) supplemented with 10% fetal calf serum, 100 IU/ml penicillin and 100 mg/ml streptomycin (Gibco, Shanghai).
RNA extraction, Microarrays and Real-time Analysis
Total RNAs were isolated from tissues or cells by TRIzol reagent, and reverse transcriptions were performed by Takara RNA PCR kit (Takara, Dalian, China) following the manufacturer's instructions. Affymetrix array hybridization and scanning were performed using Human Genome U133A 2.0 chips by Invitrogen Company (Shanghai, China). In order to quantify the transcripts of the interest genes, realtime PCR was performed using a SYBR Green Premix Ex Taq (Takara, Japan) on Light Cycler 480 (Roche, Switzerland). β-actin gene was used as an internal control. The primer sequences were listed as following: Cyr61 (Sense: 5'-ACCGCTCTGAAGGGGATCT-3'; Antisense: 5'-ACTGATGTTTACAGTTGGGCTG -3'); Sox4 (Sense: 5'-GACCTGCTCGACCTGAACC-3'; Antisense: 5'-CCGGGCTCGAAGTTAAAATCC-3'); β-actin (Sense: 5'-CTCGACACCAGGGCGTTATG-3'; Antisense: 5'-CCACTCCATGCTCGATAGGAT-3').
Small interfering RNA, Transient Transfections and Luciferase assays
Cells were plated on to six-well plates grown to 50 ~ 70% confluences and then transfected with 60 nM siGENOME non-targeting siRNA (5'-CAUGAUCCAUGGAUCGGAUU-3'), human Sox4 (Sox4-1: 5'-AUCUGAAUUGGUAcUGGAUAAU-3';Sox4-2:UCGAGCUUCCCCTAUCAUGG-3') or Cyr61 (5'-GGUCAAAGUUACCGGGCAGU-3')siGENOME SMART pool (Millipore, USA). Human Cyr61 promoter was cloned into PGL4 plasmid (Promega, USA). All the transient transfections were performed by Lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. For luciferase reporter assay, SW480 cells were seeded in 24-well plates and transfected with the indicated plasmids. Luciferase activity was measured using the Dual Luciferase Reporter Assay System (Promega, USA).
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Western Blot Cells were harvested and lysed with ice-cold lysis buffer (50 mM Tris-HCl, pH 6.8, 100 mM 2-ME, 2% w/v SDS, 10% glycerol). Proteins were separated by 10% SDS PAGE and transferred to NC membrane (Amersham Bioscience, Buckinghamshire, U.K.). After blocking with 10% nonfat milk, membranes were immunoblotted with primary antibodies, followed by HRP-linked secondary antibodies (Santa Cruz, USA). The signals were detected by SuperSignal West Pico Chemiluminescent Substrate kit (Pierce, Rockford) according to manufacturer's protocols. Anti-Sox4, Cyr61, CK2, P65, AKT and acetylated histone H3 antibodies were purchased from Cell signaling Company (USA). Protein levels were normalized to β-actin (Abcam, USA).
Chromatin Immunoprecipitation Assays
A chromatin immunoprecipitation (ChIP) assay kit was used (Upstate, USA). In short, SW480 cells were fixed with formaldehyde for 15 min. DNA was sheared to fragments at 200-1000 bp by several sonications. The chromatin were incubated and precipitated with antibodies against Sox4 antibody or IgG (Santa Cruz,USA). The primer sequences for the Cyr61 promoter regions were listed as following: -300 bp ~ -100 bp (Forward: 5'-CAGCTTATGCATACGATACT-3', Reverse: 5'-ATCGTAAGCATACC TGCAAG-3'); -2000 bp ~ -1800 bp (Forward: 5'-GGCATAGATCATTGCGGTA CT-3', Reverse: 5'-AATAGACTCACTAGCATGGA CT-3').
BrdU Incorporation Assays
A cell proliferation enzyme-linked immunosorbent assay kit (Beyotime, Shanghai, China) was employed to analyze the incorporation of BrdU during DNA synthesis following the manufacturer's protocols.
Tumor growth assay
Male BALB/c nude mice aged 6 weeks were purchased from the Experimental Animal Center of the Third Military Medical University. 6x10 5 SW480 cells stably expressing Sox4 or empty vector were injected subcutaneously to the skin under the front legs of the mouse. The mice were observed over 4 weeks for tumor formation. After the mice were sacrificed, the tumors were recovered and the wet weights of each tumor were determined. The experiments were performed using five mice per group.
Statistical Analysis
Values were shown as mean ± SEM. Two-tailed Student's t tests were used for two-group comparisons. A two-way analysis of variance (ANOVA) with Bonferroni-adjusted post tests were used for comparisons of more than two groups. GraphPad Prism 5.0 Software was employed to perform statistical analysis. Significance is displayed as * (P < 0.05), ** (P < 0.01) or *** (P < 0.001).
Results

Identification of Cyr61 as a novel Sox4 responsive gene
To screen potential transcriptional target of Sox4 in colon cancer, SW480 cells were transfected with Sox4 expression plasmids or empty vector for 24 hr. The clustering analysis of Affymetrix gene arrays revealed that 86 genes were significantly up-regulated in SW480 cells with Sox4 overexpression (p<0.05) (Data not shown). Based on this result, the gene with the largest difference in expression between two groups was Cyr61 (Fig. 1A) . We further confirmed the up-regulation of Cyr61 mRNA and protein levels by ways of Real-time PCR and Western blot (Fig. 1B-1C ). Protein levels of CK2, a downstream target gene of Sox4, were also determined by western blot. Besides, the induction of Cyr61 by Sox4 was also observed from HCT116 cells (Fig. 1D-1E) . Interestingly, Cyr61 expression was not changed by Sox2 or Sox9 overexpression (Data not shown), suggesting the specific roles of Sox4 in the up-regulation of Cyr61.
Moreover, targeted gene knockdown of endogenous Sox4 using two different small interfering RNA (siRNA) also inhibited Cyr61 expression in both cells ( Fig. 2A-2D ), suggesting that Sox4 might be a transcriptional activator of the Cyr61 gene.
Sox4 regulates down-stream signaling pathway of Cyr61
Previous studies have demonstrated that Cyr61 promotes cell proliferation and survival through activation of Akt and NF-kB/P65 signaling [13, 14] . Therefore, we examined the downstream signaling pathways in colon cancer cells with Sox4 overexpression or knockdown. As shown in Figure 3A and 3B, forced overexpression of Sox4 led to the activation of Akt and P65 in SW480 and HCT116 cells, as shown by increased phosphorylated AKT and P65 (Fig.  3A-3B ), while its knockdown led to a decreased activation of Akt and P65 signaling (Fig.  3C-3D ). Consistently, Sox4 overexpression dramatically enhanced cell proliferative capacity in colon cancer cells, which was significantly abolished by Cyr61 deficiency (Fig. 3E-3F ). Taken together, our results suggest that the up-regulation of Cyr61 represents an important mechanism for the Sox4-induced cell proliferation.
Sox4 regulates Cyr61 expression in vivo
Next, we generated SW480 cells with stable overexpression of Sox4 or empty vector (EV) for tumorigenic potential. Cells were then injected subcutaneously to the skin under the front legs of the nude mice. The tumor growth was closely monitored for another 4 weeks. As a result, the tumor size and weight was markedly increased in Sox4-overexpressed tumors compared to control tumors (Fig. 4A-4B ), suggesting that Sox4 could promote colon cancer growth in vivo. In addition, mRNA and protein levels of Cyr61 were also up-regulated by Sox4 overexpression (Fig. 4C-4D) 
Sox4 regulates Cyr61 gene transcription through promoter occupancy
Next, to seek the molecular basis for this regulation, human Cyr61 promoter region was scanned using TESS software [15] . As shown in Figure 5A , a potential Sox4 binding site was defined in the proximal region of Cyr61 promoter, located at the -168 bp ~ -162 bp relative to 
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Cyr61 expression levels were increased in colon cancer tissues Finally, we examined whether Cyr61 was differentially expressed in human colon cancer tissues. Our results revealed that mRNA levels of Cyr61 and Sox4 were significantly increased in cancer tissues, compared with pair-matched adjacent normal tissues (Fig. 6A-6B ). Moreover, a positive correlation between mRNA levels of Sox4 and Cyr61 was observed (Fig. 6C) , further indicating the transcriptional regulation of Cyr61 by Sox4.
Discussion
In the present study, we demonstrate that Sox4 up-regulates Cyr61 expression using two human colon cells. Sox4 overexpression promotes while its silencing reduced Cyr61 mRNA and protein levels. At the molecular level, we identified a potential Sox4 binding site in the proximal region of Cyr61 gene promoter. However, whether Sox4 could regulate Cyr61 expression in other cancer cells remains to be defined.
Previous studies have shown that Sox4 could directly control expression levels of several key cellular regulators in prostate cancer, such as EGFR, HSP70, Tenascin C, Frizzled-5, Patched-1, and Delta-like 1 [16] . Besides, Sox4 could interact with P53 to inhibit P53-induced cell apoptosis in hepatocellular carcinoma [17] . Moreover, Sox4 promotes epithelialmesenchymal transition in breast cancer cells by controlling Ezh2 expression and epigenetic reprogramming [18] . In colon cancer, Sox4 was shown to regulate β-catenin/T-cell factor activity and act as an agonist of Wnt signaling, through induction of casein kinase 2 [19, 20] . Here, we found that Sox4 overexpression could enhance signaling pathways of Akt and NFκb/P65. Therefore, together with these findings, our data suggest a diverse role for Sox4 in tumorigenesis.
Up-regulation of Cyr61 has been observed in many human tumors, including colon cancers [21, 22] , suggesting its important roles in tumor initiation or development. However, its molecular determinants remain largely unknown. Recent studies indicate that Cyr61 expression was negatively regulated by MicroRNA-100 and MicroRNA-22 in osteosarcoma and rheumatoid arthritis, respectively [23, 24] . Given that Sox4 expression is usually abnormally expressed in multiple cancers, our results suggest a novel mechanism for the up-regulation of Cyr61 in cancers.
In summary, our results add new insights into how Sox4 could regulate Cyr61 expression in colon cancer cells. The molecular network involving Sox4 and Cyr61 might provide a potential therapeutic option for human cancers in the future.
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